Update on anti-CTLA-4 antibodies in clinical trials

被引：63

作者：

Langer, Lee F.

Clay, Timothy M.

Morse, Michael A.

机构：

[1] Duke Univ, Med Ctr, Program Mol Therapeut, Ctr Comprehens Canc,Dept Med, Durham, NC 27710 USA

[2] Duke Univ, Med Ctr, Program Mol Therapeut, Ctr Comprehens Canc,Dept Surg, Durham, NC 27710 USA

来源：

EXPERT OPINION ON BIOLOGICAL THERAPY | 2007年 / 7卷 / 08期

关键词：

CTLA-4; CP-675,206; immunotherapy; ipilimumab; MDX-010; T-cells; tremelimumab;

D O I：

10.1517/14712598.7.8.1245

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Breaking immune tolerance against tumor self-antigens is presently an area of intense research in the design of cancer therapies. One possible method to enhance immune system activation against tumor antigens is by blocking the inhibitory co-stimulatory signals mediated by cytotoxic T lymphocyte antigen 4, (CTLA-4) expressed on activated T cells. The fully human monoclonal antibodies that are directed against human CTLA-4, ipilimumab (Medarex/Bristol-Myers Squibb) and CP-675,206 (Pfizer/Abgenix, now Amgen), have demonstrated activity against metastatic melanoma, hormone refractory prostate cancer and other malignancies. They have also uncovered unusual immune-related adverse events manifesting as self-limiting inflammatory reactions of the bowel, skin and pituitary. This article reviews preclinical development and data generated from Phase I, II and III studies with regard to the end points reported and immune-related adverse events.

引用

页码：1245 / 1256

页数：12

共 52 条

[1] Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4 [J].

Attia, P ;

Phan, GQ ;

Maker, AV ;

Robinson, MR ;

Quezado, MM ;

Yang, JC ;

Sherry, RM ;

Topalian, SL ;

Kammula, US ;

Royal, RE ;

Restifo, NP ;

Haworth, LR ;

Levy, C ;

Mavroukakis, SA ;

Nichol, G ;

Yellin, MJ ;

Rosenberg, SA .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (25) :6043-6053

[2]

ATTIA P, 2005, P AM ASS CANC RES AN

[3] Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4 [J].

Beck, Kimberly E. ;

Blansfield, Joseph A. ;

Tran, Khoi Q. ;

Feldman, Andrew L. ;

Hughes, Marybeth S. ;

Royal, Richard E. ;

Kammula, Udai S. ;

Topalian, Suzanne L. ;

Sherry, Richard M. ;

Kleiner, David ;

Quezado, Martha ;

Lowy, Israel ;

Yellin, Michael ;

Rosenberg, Steven A. ;

Yang, James C. .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (15) :2283-2289

[4]

CAMACHO LH, 2004, AM SOC CLIN ONC ANN

[5] Lymphoproliferation in CTLA-4-deficient mice is mediated by costimulation-dependent activation of CD4+ T cells [J].

Chambers, CA ;

Sullivan, TJ ;

Allison, JP .

IMMUNITY, 1997, 7 (06) :885-895

[6]

CHUNG KY, 2007, ASCO ANN M P S, V25, P3035

[7] The nature of molecular recognition by T cells [J].

Davis, SJ ;

Ikemizu, S ;

Evans, EJ ;

Fugger, L ;

Bakker, TR ;

van der Merwe, PA .

NATURE IMMUNOLOGY, 2003, 4 (03) :217-224

[8] CTLA-4 blockade enhances the therapeutic effect of an attenuated poxvirus vaccine targeting p53 in an established murine tumor model [J].

Espenschied, J ;

Lamont, J ;

Longmate, J ;

Pendas, S ;

Wang, ZD ;

Diamond, DJ ;

Ellenhorn, JDI .

JOURNAL OF IMMUNOLOGY, 2003, 170 (06) :3401-3407

[9]

EVANS L, 2002, AM SOC CLIN ONC ANN

[10]

FISCHKOFF SA, 2005, AM SOC CLIN ONC ANN

← 1 2 3 4 5 6 →